Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indiplon Driving Study Could Push Marketing Into High Gear

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer/Neurocrine's insomnia drug – which just had its user fee date extended – would still have class warnings, but could enjoy a labeling advantage over competitors.

You may also be interested in...



FDA’s Mixed Response To Indiplon Is Pfizer/Neurocrine’s Rude Awakening

Neurocrine will meet with FDA within 10 days to discuss the “approvable” and “not approvable” letters for the insomnia product.

FDA’s Mixed Response To Indiplon Is Pfizer/Neurocrine’s Rude Awakening

Neurocrine will meet with FDA within 10 days to discuss the “approvable” and “not approvable” letters for the insomnia product.

Neurocrine Likely To Seek Women’s Health Partner For Endometriosis Drug

Neurocrine expects to carry development of its gonadotrophin-releasing hormone receptor antagonist through Phase IIb before partnering.

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel